Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGRT with Capecitabine and Oxaliplatin for HCC
NCT02403544Phase 1Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Sep 2013
- Primary completion
- Jun 2016
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capecitabine and oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
capecitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02403544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02403544.